Form 4: Autonomix Medical CFO Trent N. Smith Reports Stock Option Grant

Autonomix Medical's CFO, Trent N. Smith, reported the acquisition of stock options in a recent SEC Form 4 filing.

Summary

• Trent N. Smith, CFO of Autonomix Medical, Inc., filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on June 21, 2024.
• Smith acquired options to purchase 228,087 shares of Autonomix Medical common stock at an exercise price of $1.328 per share.
• The options vest in four annual installments starting on the first anniversary of the transaction date, contingent upon Smith's continued employment.
• Following the reported transaction, Smith beneficially owns 678,087 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects a standard executive compensation practice, indicating alignment of interests between management and shareholders.

Positives

• The grant of stock options to the CFO aligns his interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company.

Industry Context

Stock option grants are a common form of executive compensation in the medical device industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the medical device industry.
• Companies like Medtronic, Boston Scientific, and Abbott also utilize stock options to incentivize their executives.
• The vesting schedule and exercise price are typical for similar grants in comparable companies.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning management's interests with the company's long-term success.
• Employees may see the grant as a sign of confidence in the company's future.

Key Dates

Keywords

Form 4, Autonomix Medical, Stock Options, Trent N. Smith, CFO, Beneficial Ownership, AMIX